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Abstract
Background: This study aimed to analyze the pattern of lymphogenous and hematogenous metastases in patients
with stage IVb thymic carcinomas and identify prognostic factors for their survivals.
Methods: Between September 1978 and October 2014, 68 patients with pathologically confirmed stage IVb
thymic carcinomas were treated at Fudan University Shanghai Cancer Center. Forty-three patients had lymph
node involvement without distant metastases, and the remaining 25 patients had hematogenous metastases.
Clinical-pathological characteristics, including age, sex, histologic subtype, tumor size, metastasis, treatment
modalities, such as surgical resection, radiotherapy, and chemotherapy, and clinical outcomes, such as overall
survival (OS) and progression free survival (PFS), were analyzed.
Results: The median follow-up time was 22 months (range, 1–126 months). The median OS of all patients with
stage IVb thymic carcinomas was 30 months, and the 5-year overall survival rate was 25.1%. The median PFS was
11 months, and the 5-year PFS was 17.9%. Stage IVb patients with lymph node involvement had a better survival
than those with distant metastasis (40 vs. 20 months, p = 0.002). Patients with myasthenia gravis had a worse
prognosis (p = 0.033). Multivariate analysis identified metastatic status as an independent prognostic factor for
OS in patients with stage IVb thymic carcinomas.
Conclusions: Patients with lymph node involvement had a better survival than those with distant metastases.
Much work remains to investigate the prognosis of patients with stage IVb thymic carcinomas and to explore
different treatment strategies for patients with lymph node involvement and distant metastases.
Keywords: Thymic carcinoma, Staging classification, Lymph node metastasis, Hematogenous metastasis
Background
Thymic carcinoma is a relatively rare mediastinal neo-
plasm characterized by extensive local invasion and
distant metastasis. Thymic carcinoma accounts for 5% of
all thymic malignancies [1], and it has a 5-year survival
of 30–50% [2–5]. No specific staging system has been
developed for thymic carcinoma because of its rarity.
Thus far, we have used the Masaoka-Koga staging system,
which is the most widely accepted system currently and
an excellent predictor of prognosis for thymoma patients
[6, 7]. The Masaoka-Koga staging system classifies both
lymphogenous and hematogenous metastases as stage
IVb tumors. Thymic carcinoma often metastasizes
lymphogenously or hematogenously, while thymoma
does not [8–10].
In general, thymic carcinomas are more invasive and
metastatic, have a higher risk of relapse, and lead to
shortened survival, compared to thymomas, which are
indolent tumors that tend to recur locally rather than
metastasize [4, 8]. Thymic carcinoma prognostic factors
include Masaoka-Koga stage [11, 12], resection status
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[11, 13], pathological subtype [1], and innominate vessel
invasion [8]. Most patients with thymic carcinoma present
with advanced disease at initial diagnosis. While advanced
thymic carcinoma portends a worse outcome, prognostic
information is needed to aid clinicians in selecting patients
with metastatic thymic carcinomas who are more likely to
obtain a good quality of life and long-term survival. Never-
theless, previous studies have mainly highlighted clinical
approaches with curative intent, paying little attention to
the subgroup of patients with stage IVb thymic carcinomas
undergoing palliative treatment. It is necessary to analyze
the patterns of lymphogenous and hematogenous metasta-
ses of thymic carcinoma and to investigate whether prog-
nosis is influenced by these metastases.
Here, we analyzed the difference in survival outcomes
between patients with lymphogenous metastasis and
those with hematogenous metastasis of thymic carcin-
oma, and we identified prognostic factors for survival of
patients with stage IVb thymic carcinomas.
Methods
Patients
We retrospectively analyzed the data from 68 patients
with stage IVb thymic carcinomas who had been treated
at Fudan University Shanghai Cancer Center between
September 1978 and October 2014. This study was
approved by the Institutional Review Board of Fudan
University Shanghai Cancer Center and conducted in
accordance with the Declaration of Helsinki. The eligi-
bility criteria were as follows. (1) Patients were diag-
nosed with histologically confirmed thymic carcinoma
based on the World Health Organization (WHO) classifi-
cation of thymic epithelial tumors [14]. The classifications
were reclassified according to WHO by experienced pa-
thologists. (2) Patient tumors that exhibited lymphogen-
ous or hematogenous metastasis were staged as stage IVb
thymic carcinoma according to the Masaoka-Koga staging
system [15], a modification of Masaoka staging system. (3)
Patients had to have complete follow-up data.
There were 68 patients with pathologically confirmed
stage IVb thymic carcinoma, including 43 patients
with lymphogenous metastasis and 25 patients with
hematogenous metastasis, and the data from these pa-
tients were evaluated in this study.
Thymic carcinoma metastasis involved two groups of
lymph nodes, the anterior (perithymic) lymph nodes
(N1) and deep intrathoracic or cervical nodes (N2), con-
sistent with the proposal of the Thymic Domain of the
Staging and Prognostic Factors Committee (TD-SPFC)
[16]. Lymphogenous or hematogenous metastasis was
determined based on radiological findings of computed
tomography, magnetic resonance imaging, or positron
emission tomography and confirmed by surgical resec-
tion or percutaneous biopsy.
Statistical analysis and definition of analysis factors
Tumors were considered completely resected if all
margins were microscopically negative. Tumors were
considered incompletely resected if the margins were
microscopically positive or if a subtotal or partial resec-
tion was performed. Tumors that disseminated were
regarded as incompletely resected, even if all nodules
were resected macroscopically. Patients who received
biopsy alone were regarded as inoperable.
Data collected included age, sex, histologic subtype,
tumor size, metastasis, treatment modalities, such as
surgical resection, radiotherapy, and chemotherapy, and
clinical outcomes, such as overall survival (OS) and
progression free survival (PFS).
The primary outcomes were OS and PFS. OS was de-
fined as the time interval from the date of surgery, or
the day of primary treatment if no surgery had been per-
formed, to the date of death from any cause or the date
when last known to be alive. PFS was defined as the time
interval from the date of surgery, or the day of primary
treatment if no surgery had been performed, to the date of
recurrence, disease progression, or the date of last follow-
up. Statistical survival analysis was performed using SPSS
(version 17.0, SPSS Inc., Chicago, IL, USA). Survival curves
were constructed using the Kaplan-Meier method and
compared using the log-rank test. Cox regression analysis
was performed for multivariate analysis. All p values were
2-sided, and statistical significance was set at p ≤ 0.05.
Results
Patient characteristics
Patient clinical and pathologic characteristics are sum-
marized in Table 1. Among 68 patients diagnosed with
stage IVb thymic carcinomas, there were 54 men and 14
women, with a mean age of 52 years (range, 16–86 years).
There was a slight preponderance of male patients
(79.4%). The most common histologic type of thymic
carcinoma was squamous cell carcinoma (n = 46). The
cases of thymic squamous cell carcinomas were graded
(G1, G2, G3). Tumor grading showed that 13.04% of the
cases were G1, 23.91% were G2, and 63.04% were G3. At
presentation 2 patients presented with myasthenia gravis
(MG) and 16 patients (23.5%) were asymptomatic. The
presenting symptoms included 24 cases with chest pain,
11 cases with cough, 7 cases with cervical mass, 5 cases
with superior vena cava syndrome, 4 cases with dyspnea
and one case with hoarseness. The mean tumor size was
9 cm (range, 3 cm–23 cm) in maximum dimension.
Lymph node metastasis
A total of 43 patients had lymph node involvement with-
out distant metastasis. Among these patients, 10 patients
had involvement of N1 nodes and 33 patients had in-
volvement of N2 nodes. In the N1 group, the mean
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number of dissected lymph nodes was 8.8 (range, 2 to
22), and the mean percentage of positive lymph nodes
was 31.8%. In the N2 group, the mean number of dis-
sected lymph nodes was 7.4 (range, 2 to 15), and the
mean percentage of positive lymph nodes was 50.39%.
Most patients with N2 nodes involvement also had N1
involvement, while 11 cases developed skip metastases.
Hematogenous metastasis
Twenty-five patients had distant metastatic disease.
Among these patients, 11 patients had lung metastases,
4 patients had bone metastases, 3 patients had liver me-
tastases, 1 patient had adrenal metastasis, and 6 patients
had multiple organ metastases at presentation. Of the 6
patients with multiple organ metastases, 2 patients had
lung and liver metastases, 2 patients had lung and bone
metastases, and 2 patients had liver and bone metasta-
ses. In addition, there were 11 patients with both lymph
node and hematogenous metastases.
Treatment
Among the 68 patients with stage IVb thymic carcinomas,
only 31 (45.6%) underwent surgical resections because
surgical resection was difficult to achieve. Surgical resec-
tion was complete in 3 patients, 28 patients received an
incomplete resection, and 37 patients (54.4%) were inop-
erable. Of the 31 patients who underwent surgical resec-
tions, 18 patients received post-operative radiotherapy,
and 6 patients received adjuvant chemoradiotherapy.
Twenty-one of 43 patients with lymph node involve-
ment underwent surgical resection (complete resection
in 3 patients and incomplete resection in 18 patients).
Twelve patients received post-operative radiotherapy, 6
patients received adjuvant chemoradiotherapy, one pa-
tient received neoadjuvant radiotherapy and 2 patients
received adjuvant chemotherapy.
Ten of 25 patients with distant metastasis underwent
surgical resection. All of the patients received an incom-
plete resection. Six patients received post-operative radio-
therapy, one patient received adjuvant chemotherapy and
3 patients received symptomatic and supportive therapy.
The distant metastatic sites of 10 patients who underwent
surgical resections were lung or bone metastasis.
Among the 37 patients without operation, 8 patients
received chemoradiotherapy, 15 patients received radio-
therapy followed by chemotherapy, 2 patients received
radiotherapy, 10 patients received chemotherapy and 2
patients received symptomatic and supportive therapy.
Of the 22 inoperable patients with lymph node involve-
ment, 7 patients received chemoradiotherapy, 7 patients
received radiotherapy followed by chemotherapy, 2 pa-
tients received radiotherapy, 5 patients received chemo-
therapy and one patient received symptomatic and
supportive therapy.
Table 1 Univariate Analysis of Progression Free Survival and







Age at diagnosis (years) 52 (16–86) 0.157 0.135
< 52 33 (48.5%)





Squamous cell carcinoma 46 (67.6%)
Neuroendocrine carcinoma 6 (8.8%)
Adenocarcinoma 4 (5.9%)
Mucoepidermoid carcinoma 1 (1.5%)






Myasthenia gravis 0.523 0.033
Yes 2 (2.9%)
No 66 (97.1%)
Tumor size 9 (3–23)cm 0.662 0.464
< 9 14 (20.6%)





Lymph node metastasis 0.281 0.361
Anterior lymph nodes 10 (14.7%)
Deep lymph nodes 33 (48.5%)




Adrenal gland 1 (1.5%)
Multiple organ 6 (8.8%)
Surgical Resection 0.055 0.224
Complete resection 3 (4.4%)
Incomplete resection 28 (41.2%)
Biopsy only 37 (54.4%)
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Of the 15 inoperable patients with distant metastasis,
one patient received chemoradiotherapy, 8 patients re-
ceived radiotherapy followed by chemotherapy, 5 pa-
tients received chemotherapy and one patient received
symptomatic and supportive therapy.
Among the 48 patients who received radiotherapy, 12
patients received two-dimensional techniques and 36
patients received 3D conformal radiation or intensity
modulated radiation therapy (IMRT). The mean radi-
ation dose delivered was 60Gy (range, 50-66Gy) with
standard fractionation.
The most frequently used regimens in our study were
CAP (cyclophosphamide + doxorubicin + cisplatin)
and EP (etoposide + cisplatin), and both regimens had
acceptable toxicity.
Survival and prognostic factors
The median follow-up time was 22 months (range, 1–
126 months). Forty-one of 68 patients with stage IVb
thymic carcinomas died of the cancer itself or from
tumor-related complications. The median OS of all pa-
tients with stage IVb thymic carcinomas was 30 months
(range, 4–126 months), and the 5-year overall survival
rate was 25.1%. The median PFS was 11 months (range,
1–116 months), and the 5-year PFS was 17.9%.
By univariate analysis, stage IVb patients with
lymph node involvement had a better survival than
those with distant metastasis, (median OS 40 vs.
20 months, p = 0.002, Fig. 1). After 11 patients with
both lymph node and hematogenous metastases were
excluded, patients with lymph node involvement still
had a better survival than those with hematogenous
metastases (p = 0.027). The same statistically signifi-
cant difference was observed between lymphogenous
and hematogenous metastases in 37 patients without
operation (p = 0.005). Patients with MG had a worse
prognosis (p = 0.033). However, patient variables such
as age, sex, tumor size, histologic subtype and surgery
resection did not show a statistical correlation with
survival (Table 1). Univariate analysis showed no as-
sociation of all factors with PFS. However, patients
with lymph node metastasis had tended to have a bet-
ter PFS (Fig. 2). The median PFS for patients with
lymph node metastasis and distant metastasis were 12
and 8 months, respectively. None of the differences
in PFS (p = 0.281) and OS (p = 0.361) reached statis-
tical significance between patients with N1 nodes in-
volvement and N2 nodes involvement. However,
patients with N1 nodes involvement had tended to
have a better PFS. There was no statistical difference
in OS between patients with or without skip metasta-
ses (p = 0.759). Moreover, there were no significant
differences in OS (p = 0.461) and PFS (p = 0.423)
based on different metastatic sites. Patients with mul-
tiple organ metastases did not have a worse OS than
patients with single organ metastasis (p = 0.125).
There was no statistical difference in OS for patients
who received an incomplete resection when com-
pared with patients with biopsy (p = 0.918).
Multivariate analysis of the three variables (metastatic
status, surgery and MG) showed that only the meta-
static status was independent prognostic factors for OS
(p = 0.005, Table 2).
Fig. 1 The overall survival curves of stage IVb thymic carcinoma
according to metastases
Fig. 2 The progression free survival curves of stage IVb thymic
carcinoma according to metastases
Yang et al. BMC Cancer  (2017) 17:217 Page 4 of 6
Discussion
Thymic carcinoma is a very rare tumor. Because of its
rarity and the absence of prospective data, there is no
specific stage classification for thymic carcinoma. We
thus far have used the Masaoka-Koga staging system
that was created for thymoma. With an increasing
number of patients who have been diagnosed with
thymic carcinoma, we found that thymic carcinomas
frequently develop lymphogenous or hematogenous
metastasis. One-third of thymic carcinoma patients re-
portedly had lymph node involvement or distant metas-
tasis in other series [17, 18], and our data matched
these findings. In general, the Masaoka-Koga staging
system, which focuses on the tumor itself, classifies
lymph node metastasis as stage IVb together with dis-
tant metastasis. Our study indicated that distant metas-
tasis was an independent prognostic factor for poor OS,
and patients with lymph node metastasis alone had
prolonged survival. This data agreed with the results of
previous studies [2, 19].
We analyzed the pattern and frequency of lymphogen-
ous metastasis and concluded that the anterior lymph
nodes were the primary lymph nodes for thymic carcin-
oma, with subsequent progression to the intrathoracic
lymph nodes, and then the extrathoracic lymph nodes. If
there was lymph node involvement, it was located in the
anterior mediastinum in approximately 74.4% of patients
with thymic carcinoma. However, thymic carcinoma
frequently (33.3%) developed skip metastases to intra-
thoracic lymph nodes excluding the anterior mediastinal
lymph nodes (n = 3), or scalene or supraclavicular lymph
nodes (n = 8). Our study showed no statistical difference
in OS between patients with or without skip metastases.
Moreover, thymic carcinoma metastasized easily to lymph
nodes, with invasion to neighboring organs and a large
primary tumor size, as reported previously [10].
Whether the presence of a positive lymph node is a
negative prognostic factor for thymic carcinoma remains
controversial. Some studies have shown the prognostic
value of positive lymph nodes [10, 20, 21], while other
studies found no difference in survival based on their
presence [2]. Park et al. reported that dissection of
more than 10 lymph nodes is required to predict prog-
nosis accurately [22]. Patients with anterior mediastinal
lymph node involvement should have a better progno-
sis, considering that anterior mediastinal lymph nodes
can be removed en bloc with the tumor in an extended
thymectomy. However, in our study, the locations of
lymph node metastases did not affect OS. We consid-
ered that the small size of these subgroups may have
undermined the ability to assess statistically significant
differences.
Many studies have confirmed that patients with
thymic carcinomas who underwent a complete resection
have a better prognosis than those receiving either in-
complete resections or no surgery. [2, 5, 21, 23, 24]
Hishida et al. analyzed 306 patients and found that stage
IVb patients who underwent complete resections of
loco-regional nodal and pulmonary metastases had rela-
tively favorable survival rates (5-year OS: 60%) [11].
However, in advanced thymic carcinoma, complete re-
section is difficult to achieve without damaging major
organs. As our study focused on stage IVb thymic car-
cinoma, complete resection may have been hampered in
these patients due to direct invasion of adjacent tissues
or metastatic spread. Thus, only 3 patients received a
complete resection. Two of these patients received post-
operation radiotherapy followed by chemotherapy, and
the other one received chemoradiotherapy. All of the pa-
tients remain alive without progression. Whether patients
with advanced thymic carcinomas could benefit from in-
complete resection remains controversial [21, 25]. Hishida
et al. found that maximal debulking surgery might confer
a survival benefit and be worth evaluating for patients
with advanced thymic tumors deemed difficult to com-
pletely resect [11], while Liu et al. failed to show an advan-
tage from debulking surgery for thymic carcinoma [26].
Yano et al. even suggested that Masaoka stage IVb thymic
carcinoma should be considered inoperable [19]. There
was no OS benefit from incomplete resection in our study
for stage IVb patients when compared with patients diag-
nosed with inoperable tumors.
The distant metastatic site was more common in lung
(n = 11), and the following sites were bone (n = 4), liver
(n = 3) and adrenal gland (n = 1). Considering most
patients with distant metastasis are difficult to receive
surgical resection, we analyzed the difference between
lymph node metastasis and distant metastasis in 37
patients without operation. Our results show that the
survival outcomes of patients with distant metastasis
(n = 15) are worse than those of patients with lymph
node metastasis (n = 22). Based on prognosis, the
Masaoka-Koga staging system definition of stage IVb
thymic carcinoma as a tumor that has either lympho-
genously or hematogenously metastasized is imprecise.
Table 2 Multivariate Analysis of Prognostic Factors Associated
with Overall Survival in 68 Stage IVb Thymic Carcinomas




Yes vs. no 3.807 (0.465, 31.153) 0.213
Surgery
Yes vs. no 1.055 (0.766, 1.453) 0.744
Metastasis
Lymphogenous vs. hematogenous 2.580 (1.341, 4.967) 0.005
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Our study has limitations typical of the retrospective
nature of the data collection and heterogeneity of treat-
ments. However, this kind of bias is intrinsic to the study
strategy and thus unavoidable. Furthermore, because of
the low incidence and indolent behavior of thymic carcin-
oma, few patients have been analyzed. Thus, large-scale
prospective trials and collaborative efforts will be needed
to provide sufficient prognostic information to establish
an appropriate staging system and to predict survival and
recurrence for patients with this rare disease.
Conclusions
In conclusion, our results demonstrate that patients with
stage IVb lymph node metastasis may have a better sur-
vival than patients with distant metastases. Much work re-
mains to clarify the classification scheme and investigate
the prognosis of patients with thymic carcinoma.
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